- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03385018
Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)
Multicenter Randomized Controlled Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)
Although Laparoscopic gastrectomy for both early and locally advanced gastric cancer has gained popularity, the use of laparoscopic total gastrectomy for proximal advanced gastric cancer is still limited to some experienced surgeons, because of its technical difficulties in D2 lymph node dissection and anastomoses.
Some retrospective and cohort studies regarding laparoscopic total gastrectomy with lymph node dissection suggested the likelihood of application of laparoscopic surgery for proximal gastric cancer. However, there has been no randomized clinical trial comparing results of laparoscopic total gastrectomy with D2 lymph node dissection with open conventional surgery.
Therefore, we aimed to verify the efficacy of laparoscopic total gastrectomy with D2(D2-10) lymph node dissection, technical and oncologic safety compared with open surgery via multicenter randomized clinical trial.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Woo Jin Hyung, MD, PhD
- Phone Number: +82-2-2228-2100
- Email: wjhyung@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Recruiting
- Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
-
Contact:
- Woo Jin Hyung, MD
- Phone Number: +82-2-2228-2100
- Email: WJHYUNG@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who are over 20 and below 80 years old
- Patients who have performance status of ECOG 0 or 1
- Patients with American Society of Anesthesiology score of class I to III
- Patients who are diagnosed with gastric adenocarcinoma not involving Z-line by endoscopy with biopsy
- Patients with tumors which can be curatively resected by total gastrectomy with lymph node dissection based on preoperative study
- Patients who have primary gastric carcinoma invaded into over muscle propria, and not into adjacent organ in preoperative studies (cT2 ~ cT4a)
- Patients who have no metastasis to lymph nodes or limited metastasis to perigastric lymph node metastasis in preoperative studies (cN0 ~ cN2)
- Patients who agree with participating in the clinical study with informed consents
- Patients who can be followed for at least 3 years after study enrollment
Exclusion Criteria:
- Patients who have possibility of distant metastasis in preoperative studies
- Patients who have history of gastric resection with any cause
- Patients who have complications (bleeding or obstruction) of gastric cancer
- Patients who are treated by chemo(radio)therapy or endoscopic submucosal dissection for gastric cancer
- Patients who are diagnosed and treated with other malignancies within 5 years
- Vulnerable patients
- Patients who participating or participated in other clinical trial within 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Laparoscopic group
Arm Description: Laparoscopic radical total gastrectomy with D2 (or D2-#10) lymph node dissection
|
|
Active Comparator: Open group
Open radical total gastrectomy with D2 (or D2-#10) lymph node dissection
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3 year relapse-free survival
Time Frame: 3 years after surgery
|
Non-inferiority of 3 year relapse-free survival rate after laparoscopic radical total gastrectomy and lymphadenectomy for locally advanced gastric cancer comparing with open conventional surgery. The "event" of relapse-free survival is defined as "recurrence" after 4 weeks of operation. The "censoring" is defined as non-traceable patient who cannot be confirmed with recurrence or patient who are alive without recurrence until follow-up. The "relapse-free survival time" is defined as the time from surgery to "event" or "censoring". |
3 years after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3 year overall survival rate
Time Frame: 3 years after surgery
|
3 years after surgery
|
|
5 year relapse-free and overall survival
Time Frame: 5 years after surgery
|
5 years after surgery
|
|
Morbidity (early period)
Time Frame: from Operation day until POD 21
|
from Operation day until POD 21
|
|
Morbidity (late period)
Time Frame: from POD (Post-Operative Day) 22 until 5 years after surgery
|
from POD (Post-Operative Day) 22 until 5 years after surgery
|
|
Mortality
Time Frame: at POD 30
|
death with any cause
|
at POD 30
|
Mortality
Time Frame: at POD 90
|
death with any cause
|
at POD 90
|
Quality of life(EORTC QLQ-C30)
Time Frame: at POD 21
|
Quality of life measured by EORTC QLQ-C30(Version 3) The questionnaire was designed to measure cancer patients' physical, psychological and social functions.
The questionnaire is composed of 5 multiitem scales (physical, role, social, emotional and cognitive functioning) and 9 single items (pain, fatigue, financial impact, appetite loss, nausea/vomiting, diarrhea, constipation, sleep disturbance and quality of life).
|
at POD 21
|
Quality of life(EORTC QLC STO22)
Time Frame: at POD 21
|
Quality of life measured by EORTC QLC STO22.
The EORTC QLQ-STO 22 module contains 22 items in a similar layout and response format to the EORTC QLQ-C30.
The hypothesised scale structure of the module consists of five scales (dysphagia, eating restrictions, pain, reflux and anxiety) and three single items (dry mouth, body image and hair loss).
|
at POD 21
|
Quality of life(EORTC QLQ-C30)
Time Frame: 3 months after surgery
|
Quality of life measured by EORTC QLQ-C30(Version 3)
|
3 months after surgery
|
Quality of life(EORTC QLC STO22)
Time Frame: 3 months after surgery
|
Quality of life measured by EORTC QLC STO22.
The EORTC QLQ-STO 22 module contains 22 items in a similar layout and response format to the EORTC QLQ-C30.
The hypothesised scale structure of the module consists of five scales (dysphagia, eating restrictions, pain, reflux and anxiety) and three single items (dry mouth, body image and hair loss).
|
3 months after surgery
|
Quality of life(EORTC QLQ-C30)
Time Frame: 12 months after surgery
|
Quality of life measured by EORTC QLQ-C30(Version 3)
|
12 months after surgery
|
Quality of life(EORTC QLC STO22)
Time Frame: 12 months after surgery
|
Quality of life measured by EORTC QLC STO22.
The EORTC QLQ-STO 22 module contains 22 items in a similar layout and response format to the EORTC QLQ-C30.
The hypothesised scale structure of the module consists of five scales (dysphagia, eating restrictions, pain, reflux and anxiety) and three single items (dry mouth, body image and hair loss).
|
12 months after surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2017-0940
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach
-
Guangdong Provincial Hospital of Traditional Chinese...UnknownLaparoscopic Gastrectomy | Laparoscopic Bursectomy | A Left Outside Bursa Omentalis ApproachChina
-
Fujian Medical UniversityThe First Affiliated Hospital of Nanchang University; Chinese PLA General Hospital and other collaboratorsNot yet recruitingGastric Cancer | Robotic GastrectomyChina
-
Seoul National University Bundang HospitalRecruitingGastric Cancer | Gastric AdenocarcinomaKorea, Republic of
-
Southwest Hospital, ChinaThe First Affiliated Hospital of Nanchang University; Sun Yat-sen University; Chinese PLA General Hospital and other collaboratorsUnknown
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanCompleted
-
Southwest Hospital, ChinaCompleted
-
Peking UniversityThe First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer... and other collaboratorsRecruiting
-
Fujian Medical UniversityEnrolling by invitation
-
N.N. Petrov National Medical Research Center of...Active, not recruitingColonic Neoplasms MalignantRussian Federation
-
G.V. Bondar Republican Cancer CenterI.M. Sechenov First Moscow State Medical University; Donetsk National Medical...Active, not recruiting